Synergy Between Readthrough and Nonsense Mediated Decay Inhibition in a Murine Model of Cystic Fibrosis Nonsense Mutations

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Jan 5

PMID 33396210

Citations 15

Authors

Daniel R McHugh

Calvin U Cotton

Craig A Hodges

Affiliations

Soon will be listed here.

Abstract

Many heritable genetic disorders arise from nonsense mutations, which generate premature termination codons (PTCs) in transcribed mRNA. PTCs ablate protein synthesis by prematurely terminating the translation of mutant mRNA, as well as reducing mutant mRNA quantity through targeted degradation by nonsense-mediated decay (NMD) mechanisms. Therapeutic strategies for nonsense mutations include facilitating ribosomal readthrough of the PTC and/or inhibiting NMD to restore protein function. However, the efficacy of combining readthrough agents and NMD inhibitors has not been thoroughly explored. In this study, we examined combinations of known NMD inhibitors and readthrough agents using functional analysis of the protein in primary cells from a mouse model carrying a G542X nonsense mutation in . We observed synergy between an inhibitor of the NMD component SMG-1 (SMG1i) and the readthrough agents G418, gentamicin, and paromomycin, but did not observe synergy with readthrough caused by amikacin, tobramycin, PTC124, escin, or amlexanox. These results indicate that treatment with NMD inhibitors can increase the quantity of functional protein following readthrough, and that combining NMD inhibitors and readthrough agents represents a potential therapeutic option for treating nonsense mutations.

Citing Articles

A W1282X cystic fibrosis mouse allows the study of pharmacological and gene-editing therapeutics to restore CFTR function.

Michicich M, Traylor Z, McCoy C, Valerio D, Wilson A, Schneider M J Cyst Fibros. 2024; 24(1):164-174.

PMID: 39532588 PMC: 11788034. DOI: 10.1016/j.jcf.2024.10.008.

Promoting readthrough of nonsense mutations in CF mouse model: Biodistribution and efficacy of NV848 in rescuing CFTR protein expression.

Fiduccia I, Corrao F, Zizzo M, Perriera R, Genovese F, Vitale E Mol Ther. 2024; 32(12):4514-4523.

PMID: 39473179 PMC: 11638873. DOI: 10.1016/j.ymthe.2024.10.028.

Therapeutic Nonsense Suppression Modalities: From Small Molecules to Nucleic Acid-Based Approaches.

Morais P, Zhang R, Yu Y Biomedicines. 2024; 12(6).

PMID: 38927491 PMC: 11201248. DOI: 10.3390/biomedicines12061284.

Han X, Li D, Zhu Y, Schneider-Futschik E ACS Pharmacol Transl Sci. 2024; 7(4):933-950.

PMID: 38633590 PMC: 11019735. DOI: 10.1021/acsptsci.3c00362.

En Route to Targeted Ribosome Editing to Replenish Skin Anchor Protein LAMB3 in Junctional Epidermolysis Bullosa.

Wimmer B, Friedrich A, Poeltner K, Edobor G, Mosshammer C, Temaj G JID Innov. 2024; 4(1):100240.

PMID: 38282649 PMC: 10810840. DOI: 10.1016/j.xjidi.2023.100240.

References

Koller B, Kim H, Latour A, Brigman K, Boucher Jr R, Scambler P . Toward an animal model of cystic fibrosis: targeted interruption of exon 10 of the cystic fibrosis transmembrane regulator gene in embryonic stem cells. Proc Natl Acad Sci U S A. 1991; 88(23):10730-4. PMC: 53004. DOI: 10.1073/pnas.88.23.10730. View

De Lisle R, Borowitz D . The cystic fibrosis intestine. Cold Spring Harb Perspect Med. 2013; 3(9):a009753. PMC: 3753720. DOI: 10.1101/cshperspect.a009753. View

McHugh D, Steele M, Valerio D, Miron A, Mann R, LePage D . A G542X cystic fibrosis mouse model for examining nonsense mutation directed therapies. PLoS One. 2018; 13(6):e0199573. PMC: 6010256. DOI: 10.1371/journal.pone.0199573. View

Hermann T . Aminoglycoside antibiotics: old drugs and new therapeutic approaches. Cell Mol Life Sci. 2007; 64(14):1841-52. PMC: 11136281. DOI: 10.1007/s00018-007-7034-x. View

Dekkers J, Berkers G, Kruisselbrink E, Vonk A, De Jonge H, Janssens H . Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis. Sci Transl Med. 2016; 8(344):344ra84. DOI: 10.1126/scitranslmed.aad8278. View

Sermet-Gaudelus I, Clancy J, Nichols D, Nick J, De Boeck K, Solomon G . Antisense oligonucleotide eluforsen improves CFTR function in F508del cystic fibrosis. J Cyst Fibros. 2018; 18(4):536-542. PMC: 7227803. DOI: 10.1016/j.jcf.2018.10.015. View

Du M, Keeling K, Fan L, Liu X, Kovacs T, Sorscher E . Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model. J Mol Med (Berl). 2006; 84(7):573-82. DOI: 10.1007/s00109-006-0045-5. View

Valley H, Bukis K, Bell A, Cheng Y, Wong E, Jordan N . Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells. J Cyst Fibros. 2018; 18(4):476-483. DOI: 10.1016/j.jcf.2018.12.001. View

Johnson L, Olsen J, Sarkadi B, Moore K, Swanstrom R, Boucher R . Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis. Nat Genet. 1992; 2(1):21-5. DOI: 10.1038/ng0992-21. View

10.

Gonzalez-Hilarion S, Beghyn T, Jia J, Debreuck N, Berte G, Mamchaoui K . Rescue of nonsense mutations by amlexanox in human cells. Orphanet J Rare Dis. 2012; 7:58. PMC: 3562214. DOI: 10.1186/1750-1172-7-58. View

11.

Clancy J, Bebok Z, Ruiz F, King C, Jones J, Walker L . Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med. 2001; 163(7):1683-92. DOI: 10.1164/ajrccm.163.7.2004001. View

12.

Du M, Jones J, Lanier J, Keeling K, Lindsey J, Tousson A . Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene. J Mol Med (Berl). 2002; 80(9):595-604. DOI: 10.1007/s00109-002-0363-1. View

13.

Neu-Yilik G, Amthor B, Gehring N, Bahri S, Paidassi H, Hentze M . Mechanism of escape from nonsense-mediated mRNA decay of human beta-globin transcripts with nonsense mutations in the first exon. RNA. 2011; 17(5):843-54. PMC: 3078734. DOI: 10.1261/rna.2401811. View

14.

Bidou L, Bugaud O, Belakhov V, Baasov T, Namy O . Characterization of new-generation aminoglycoside promoting premature termination codon readthrough in cancer cells. RNA Biol. 2017; 14(3):378-388. PMC: 5367250. DOI: 10.1080/15476286.2017.1285480. View

15.

Yu H, Liu X, Huang J, Zhang Y, Hu R, Pu J . Comparison of read-through effects of aminoglycosides and PTC124 on rescuing nonsense mutations of HERG gene associated with long QT syndrome. Int J Mol Med. 2013; 33(3):729-35. DOI: 10.3892/ijmm.2013.1601. View

16.

Beznoskova P, Gunisova S, Valasek L . Rules of UGA-N decoding by near-cognate tRNAs and analysis of readthrough on short uORFs in yeast. RNA. 2016; 22(3):456-66. PMC: 4748822. DOI: 10.1261/rna.054452.115. View

17.

Berger A, Knudson A, Pandolfi P . A continuum model for tumour suppression. Nature. 2011; 476(7359):163-9. PMC: 3206311. DOI: 10.1038/nature10275. View

18.

Gopalsamy A, Bennett E, Shi M, Zhang W, Bard J, Yu K . Identification of pyrimidine derivatives as hSMG-1 inhibitors. Bioorg Med Chem Lett. 2012; 22(21):6636-41. DOI: 10.1016/j.bmcl.2012.08.107. View

19.

Davis S, Ratjen F . Reduced lung function in cystic fibrosis: a primary or secondary phenotype?. Am J Respir Crit Care Med. 2008; 178(1):2-3. DOI: 10.1164/rccm.200804-502ED. View

20.

Azzalin C, Lingner J . The human RNA surveillance factor UPF1 is required for S phase progression and genome stability. Curr Biol. 2006; 16(4):433-9. DOI: 10.1016/j.cub.2006.01.018. View